145013-67-8

Upstream product

• 145013-65-6 4-Chloro-8-methoxy-5-nitroquinoline 
• 98-80-6 phenylboronic acid 
• 99-59-2 3-amino-4-methoxynitrobenzene 
• 299966-23-7 8-methoxy-5-nitroquinoline-4-one 
• 103028-31-5 4-bromo-8-methoxyquinoline 
• 21269-34-1 4-hydroxy-8-methoxyquinoline 
• 16778-21-5 4-chloro-8-methoxyquinoline 

Downstream Products

• 145013-78-1 5-Azido-6-bromo-8-methoxy-4-phenyl-quinoline 
• 145013-75-8 5-Azido-8-methoxy-4-phenyl-quinoline 
• 149221-78-3 5-Azido-8-methoxy-4-phenyl-quinoline-6-carboxylic acid methyl ester 
• 149221-76-1 Methyl 5-Amino-8-methoxy-4-phenylquinoline-6-carboxylate 
• 1027297-98-8 5-Amino-8-methoxy-4-phenyl-quinoline-6-carboxylic acid 
• 149221-77-2 5-amino-8-methoxy-4-phenylquinoline-6-carbonitrile 
• 145013-73-6 6-bromo-8-methoxy-4-phenylquinoline-5-amine 
• 117694-98-1 norsegoline 
• 145013-70-3 5-amino-8-methoxy-4-phenylquinoline 

Relevant academic research and scientific papers

Divergent Syntheses of Pyridoacridine Alkaloids via Palladium-Catalyzed Reductive Cyclization with Nitro-Biarenes

A divergent and novel protocol for the preparation of both pyrido[2,3,4-kl]acridine and pyrido[4,3,2-kl]acridine alkaloids was developed. This method featured the remote palladium-catalyzed reductive cyclization with Mo(CO)6 as reductant. A wide range of substrates including three types of nitro arenes were tolerated and afforded corresponding products in good to excellent yields. This method has been successfully applied to the total synthesis of norsegoline, styelsamine C and the skeleton of necatorone.

Nitrohydroxyquinoline derivative and preparation method and application thereof

The invention discloses a nitrohydroxyquinoline derivative and a preparation method and application thereof. Specifically, the invention discloses a compound shown as a general formula (I), a preparation method of the compound, a pharmaceutical composition containing the compound, and an application of the compound in treatment on infectious diseases or cancers. The compound disclosed by the invention has different anti-tumor activities and can be developed into a medicine for treating tumors. The definition of each group in the general formula (I) is the same as that in the specification.

Palladium-catalysed cross-coupling reactions of arylboronic acids with π-deficient heteroaryl chlorides

The palladium-catalysed cross-coupling reactions of arylboronic acids with a variety of π-deficient heteroaryl chlorides proceed in high yield. [1,4-Bis(diphenylphosphino)butane]palladium(II) dichloride was found to be a very satisfactory catalyst for monocyclic heteroaryl chlorides, whereas tetrakis(triphenylphosphine)palladium(O) was found to be excellent for a range of chloroquinoline derivatives.